You are here

Article Text

Article menu
Download PDFPDF
Infographic
Infographic. Tramadol: should it be banned in athletes while competing, particularly in road cycling?
  1. Joao Gabriel Baltazar-Martins1,
  2. María del Mar Plata2,
  3. Jesús Muñoz-Guerra3,
  4. Gloria Muñoz4,
  5. Daniel Carreras4,
  6. Juan Del Coso1
  1. 1 Exercise Physiology Laboratory, Universidad Camilo Jose Cela, Villanueva de la Cañada, Spain
  2. 2 Department of Education, AEPSAD, Madrid, Spain
  3. 3 Jefe de Prevención y control del Dopaje, AEPSAD, Madrid, Spain
  4. 4 Doping Control Laboratory, AEPSAD, Madrid, Spain
  1. Correspondence to Dr Juan Del Coso, Exercise Physiology Laboratory, Universidad Camilo Jose Cela, Villanueva de la Cañada 28692, Spain; jdelcoso{at}ucjc.edu

https://doi.org/10.1136/bjsports-2018-100473

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Tramadol is a synthetic opioid widely used for the management of pain in sport setting.1 Tramadol is considered an effective substance to reduce acute and chronic pain because it acts by binding to the μ-opioid receptor to induce analgesia and sedation. However, tramadol also inhibits serotonin and norepinephrine reuptake and thus, it might play a role in the regulation of mood. In the past years, tramadol has caught attention of media and antidoping authorities because this substance might be the subject of abuse in some sports, notably cycling.2 WADA determined that the use of some narcotics are …

    View Full Text

    Footnotes

    • Contributors JGB-M drafted the infographics with the indications of JDC. All the authors reviewed the infographic and the accompanying text.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Provenance and peer review Not commissioned; externally peer reviewed.